- Home
- CPRX vs ADPT Comparison
CPRX vs ADPT Comparison
Compare CPRX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | ADPT |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CPRX | ADPT |
|---|---|---|
| Price | $24.17 | $15.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $32.60 | $16.60 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.94 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $578,196,000.00 | $252,754,000.00 |
| Revenue This Year | $19.87 | $50.81 |
| Revenue Next Year | $7.21 | $1.17 |
| P/E Ratio | $13.83 | ★ N/A |
| Revenue Growth | 25.56 | ★ 42.57 |
| 52 Week Low | $19.05 | $5.81 |
| 52 Week High | $26.58 | $20.76 |
Technical Indicators
Market Signals| Indicator | CPRX | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 66.20 | 46.31 |
| Support Level | $22.67 | $14.58 |
| Resistance Level | $23.84 | $16.26 |
| Average True Range (ATR) | 0.68 | 1.02 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 70.80 | 18.77 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).